Merck & Company, Inc. (NYSE: MRK), Pfizer, Inc. (NYSE: PFE) – Pfizer, Merck COVID-19 Pills To Be Launched In The United States This Month; Other countries have to wait: WSJ
In a race with Merck & Co Inc (NYSE: MRK) to Bring Antiviral Drugs to Market, Pfizer Inc (NYSE: PFE) CEO Albert Bourla said that Wall Street Journal CEO Council that he expects his antiviral pill to hit the US market later this month.
- Data from Pfizer’s pill, Paxlovid, showed an 89 percent reduction in COVID-19-related hospitalizations or deaths in an interim analysis compared to placebo in patients treated within three days of the onset of symptoms.
- Pfizer also previously said the US would pay $ 5.29 billion for 10 million courses of treatment.
- Merck, meanwhile, narrowly won the support of an FDA AdComm as panelists focused on the effectiveness of the Merck pill and what caused this decline in preventing hospital stays and fatalities from 50% to 30%.
- Most of the publicly announced supply contracts relate to rich countries.
- Public health experts have raised concerns that the pills may arrive months later in emerging markets, delaying treatment for people.
- Generic versions of the Pfizer pill won’t hit low and middle-income countries until mid-2022 at the earliest, said Charles Gore, executive director of the Medicines Patent Pool.
- In addition to challenges, most low-income countries lack adequate testing and diagnostic tools to identify patients early enough for treatments to help.
- WHO said the ACT accelerator will need $ 3.5 billion from donors by next September to support the delivery of COVID-19 therapeutics. So far, 39 million US dollars have been poured in.
- Price action: PFE shares are down 0.34% to $ 51.31, while MRK shares are down 1.87% to $ 72.05 during the market session last Check Tuesday.
Â© 2021 Benzinga.com. Benzinga does not offer investment advice. All rights reserved.